Skip to content
Open access · OA via OpenAlex

TARGETING AGING WITH METFORMIN (TAME)

Nir Barzilai

Innovation in Aging · 2017 · ▲ 30 citations

Abstract

Metformin is one drug that targets the biology of aging and extends life- and health-span in animals. It is used for the treatment of and to delay type 2 diabetes mellitus (T2DM), with an over 60 years outstanding safety record. Metformin use is also associated with lower rates of cancer, CVD, all-cause mortality and possibly less cognitive decline. We designed TAME, a placebo controlled, multi-center study in ~3000 elderly aged 65–79, with a novel primary outcome of delaying the incidence of a composite of multiple age-related diseases. Additional outcomes relate to geriatric syndromes and functional health. The study was developed in consultation with the FDA to obtain a new FDA indication to target aging. This indication would allow industry to justify the development of next-generation drugs to target aging and will further extend healthy life span in the next decade, utilizing the experimental template provided by TAME.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1093/geroni/igx004.2682
Canonical
link ↗
Fetched
2026-10-08 MST

Cite this

APA
Barzilai, N. (2017). TARGETING AGING WITH METFORMIN (TAME). <em>Innovation in Aging</em>. https://doi.org/10.1093/geroni/igx004.2682
Vancouver
Barzilai N. TARGETING AGING WITH METFORMIN (TAME). Innovation in Aging. 2017. doi:10.1093/geroni/igx004.2682.
BibTeX
@article{nir2017TARGET, title = {TARGETING AGING WITH METFORMIN (TAME)}, author = {Nir Barzilai}, journal = {Innovation in Aging}, year = {2017}, doi = {10.1093/geroni/igx004.2682}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings